KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy for the treatment of advanced melanoma and metastatic non-small
cell lung cancer in patients whose disease has progressed after other
therapies, received the Prix Galien USA 2015 Award for Best
Biotechnology Product.
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Lung Cancer | Melanoma | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer